Su1588 Helicobacter Hepaticus Infection Promotes Hepatitis and Foci of Cellular Alteration in Farnesoid X Receptor (FXR) Deficient Mice

2012 ◽  
Vol 142 (5) ◽  
pp. S-972-S-973
Author(s):  
Alton G. Swennes ◽  
Alexis García ◽  
Nicola M. Parry ◽  
Kvin Lertpiriyapong ◽  
James G. Fox
PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e106764 ◽  
Author(s):  
Alton G. Swennes ◽  
Alexander Sheh ◽  
Nicola M. A. Parry ◽  
Sureshkumar Muthupalani ◽  
Kvin Lertpiriyapong ◽  
...  

2003 ◽  
Vol 278 (43) ◽  
pp. 41930-41937 ◽  
Author(s):  
Tineke Kok ◽  
Christian V. Hulzebos ◽  
Henk Wolters ◽  
Rick Havinga ◽  
Luis B. Agellon ◽  
...  

2014 ◽  
Vol 448 (1) ◽  
pp. 50-55 ◽  
Author(s):  
Weibin Wu ◽  
Xijun Liu ◽  
Xiaomin Peng ◽  
Ruyi Xue ◽  
Lingling Ji ◽  
...  

2005 ◽  
Vol 46 (12) ◽  
pp. 2595-2604 ◽  
Author(s):  
Elyisha A. Hanniman ◽  
Gilles Lambert ◽  
Tanya C. McCarthy ◽  
Christopher J. Sinal

2008 ◽  
Vol 134 (4) ◽  
pp. A-644-A-645
Author(s):  
Sigrid Heinsbroek ◽  
Kevin J. Maloy ◽  
Philip Ahern ◽  
Mark Asquith ◽  
Sofia M. Buonocore ◽  
...  

2020 ◽  
Author(s):  
Shengmin Yan ◽  
Bilon Khambu ◽  
Xiaoyun Chen ◽  
Zheng Dong ◽  
Grace Guo ◽  
...  

ABSTRACTObjectiveThe gut microbiota (GM) can have complicated and often undetermined interactions with the function of many organs in the body. GM is altered in a variety of liver diseases, but the significance of such changes on the liver disease is still unclear. Hepatic autophagy deficiency causes liver injury accompanied with cholestasis. Here, we investigated the impact of such hepatic changes on GM and in turn the effect of gut dysbiosis on liver injury.DesignFecal microbiota from mice with liver-specific loss of autophagy-related gene 5 (Atg5), Atg5Δhep mice, were analyzed by 16S sequencing. Antibiotics (ABX) was used to modulate GM in mice. Cholestyramine was used to reduce the enterohepatic bile acid (BA) level. The functional role of fibroblast growth factor 15 (FGF15) and ileal farnesoid X receptor (FXR) was examined in mice over-expressing FGF15 gene, or given a fibroblast growth factor receptor 4 (FGFR4) inhibitor.ResultsThe composition of GM was significantly changed with a notable increase of BA-metabolizing bacteria in Atg5Δhep mice, leading to a lower proportion of tauro-conjugated BAs and a higher proportion of unconjugated BAs in the intestine, which markedly activated ileal FXR with an increased expression of FGF15. ABX or cholestyramine treatment exacerbated liver injury and ductular reaction, and decreased FGF15 expression, whereas modulating FGF15 signaling altered liver phenotypes in the autophagy-deficient mice.ConclusionGut dysbiosis can remedy liver injury in Atg5Δhep mice through the FXR-FGF15 signaling. Antibiotics use in the condition of liver injury may have unexpected adverse consequences via the gut-liver axis.SHORT SUMMARYWhat is already known about this subject?Gut microbiota (GM) can be altered during hepatic pathogenesis.GM are involved in bile acid (BA) metabolism.Autophagy deficiency in the liver disrupts BA homeostasis and causes cholestatic injury.What are the new findings?Deficiency of autophagy in the liver causes alteration of GM, which leads to a higher proportion of BA-metabolizing bacteria.GM contribute to the activation of ileal farnesoid X receptor (FXR) and a higher expression of fibroblast growth factor 15 (FGF15) in autophagy deficient condition in the liver, which is associated with decreased levels of conjugated BAs and increased levels of unconjugated BAs in the intestine.Manipulations that lead to GM alteration, intestinal BA signaling, or FGF15 signaling can all modulate the liver phenotype.BA and GM together can act as a sensor to liver injury to trigger FGF15-mediated protective mechanism.How might it impact on clinical practice in the foreseeable future?These findings indicate that gut dysbiosis in the scenario of liver disease can be beneficial, suggesting cautions should be exercised in the use of antibiotics during specific liver diseases.If antibiotics need to be used in patients with liver diseases it may be beneficial to enhance the FXR-FGF15 feedback signaling to retain the protective effect of GM.


2009 ◽  
Vol 46 (3) ◽  
pp. 491-504 ◽  
Author(s):  
R. Read ◽  
G. Hansen ◽  
J. Kramer ◽  
R. Finch ◽  
L. Li ◽  
...  

Ectonucleoside triphosphate diphosphohydrolase type 5 (ENTPD5, also CD39L4) is a soluble enzyme that hydrolyzes purine nucleoside diphosphates. Genetic inactivation of ENTPD5 in mice ( Entpd5-/-) resulted in 2 major histopathologic lesions: hepatopathy and aspermia. The hepatopathy was progressive and characterized by centrilobular hepatocyte hypertrophy, oval cell proliferation, bile staining of Kupffer cells, and hepatocyte degeneration with increasing incidence and severity of degenerative lesions, development of multiple foci of cellular alteration, and hepatocellular neoplasia with age. Greatly increased proliferation of hepatocytes in young adult as well as aged Entpd5-/- mice was demonstrated by Ki67 immunohistochemistry and 5î-bromo-3î-deoxyuridine incorporation. Of 15 Entpd5-/- mice between 44 and 69 weeks of age, all showed foci of cellular alteration in the liver, and at least 6 of 15 developed hepatocellular carcinoma (HCC), hepatocellular adenoma, or both. Significantly, none of these lesions were observed in 13 wild-type Entpd5++ littermates. These findings, combined with the historically low incidence (about 5%) of HCC in mice up to 2 years of age with the same genetic background, strongly suggest that loss of Entpd5 promotes hepatocellular neoplasia in mice. In humans, ENTPD5 has been found to be identical to the PCPH proto-oncogene, and dysregulation of this gene has been demonstrated in some human cancers. This mouse model could contribute to the understanding of the influence of ENTPD5/PCPH on cellular proliferation and neoplasia.


2005 ◽  
Vol 73 (2) ◽  
pp. 912-920 ◽  
Author(s):  
Jeremy A. Peña ◽  
Arlin B. Rogers ◽  
Zhongming Ge ◽  
Vivian Ng ◽  
Sandra Y. Li ◽  
...  

ABSTRACT Clinical and experimental evidence has demonstrated the potential role of probiotics in the prevention or treatment of inflammatory bowel disease. Probiotic clones with direct immunomodulatory activity may have anti-inflammatory effects in the intestine. We investigated the roles of tumor necrosis factor alpha (TNF-α)-inhibitory Lactobacillus clones with a pathogen-induced murine colitis model. Murine-derived probiotic lactobacilli were selected in vitro for their ability to inhibit TNF-α secretion by Helicobacter hepaticus-stimulated macrophages. Interleukin-10 (IL-10)-deficient mice were treated with probiotic Lactobacillus reuteri in combination with Lactobacillus paracasei and then challenged with H. hepaticus. Ten weeks postinoculation, the severity of typhlocolitis was assessed by histologic examination of the cecocolic region. Intestinal proinflammatory cytokine responses were evaluated by real-time quantitative reverse transcriptase PCR and immunoassays, and the quantities of intestinal H. hepaticus were evaluated by real-time PCR. Intestinal colonization by TNF-α-inhibitory lactobacilli reduced intestinal inflammation in H. hepaticus-challenged IL-10-deficient mice despite similar quantities of H. hepaticus in cocolonized animals. Proinflammatory colonic cytokine (TNF-α and IL-12) levels were lowered in Lactobacillus-treated animals. In this H. hepaticus-challenged IL-10-deficient murine colitis model, lactobacilli demonstrated probiotic effects by direct modulation of mucosal inflammatory responses.


Biochimie ◽  
2015 ◽  
Vol 115 ◽  
pp. 86-92 ◽  
Author(s):  
Wei-Bin Wu ◽  
Yuan-Yuan Chen ◽  
Bo Zhu ◽  
Xiao-Min Peng ◽  
Song-Wen Zhang ◽  
...  

2004 ◽  
Vol 72 (2) ◽  
pp. 1116-1125 ◽  
Author(s):  
James G. Fox ◽  
Arlin B. Rogers ◽  
Mark T. Whary ◽  
Zhongming Ge ◽  
Nancy S. Taylor ◽  
...  

ABSTRACT Campylobacter jejuni continues to be a leading cause of bacterial enteritis in humans. However, because there are no readily available animal models to study the pathogenesis of C. jejuni-related diseases, the significance of potential virulence factors, such as cytolethal distending toxin (CDT), in vivo are poorly understood. Mice deficient in NF-κB subunits (p50−/− p65+/−) in a C57BL/129 background are particularly susceptible to colitis induced by another enterohepatic microaerobe, Helicobacter hepaticus, which, like C. jejuni, produces CDT. Wild-type C. jejuni 81-176 and an isogenic mutant lacking CDT activity (cdtB mutant) were inoculated into NF-κB-deficient (3X) and C57BL/129 mice. Wild-type C. jejuni colonized 29 and 50% of the C57BL/129 mice at 2 and 4 months postinfection (p.i.), respectively, whereas the C. jejuni cdtB mutant colonized 50% of the C57BL/129 mice at 2 p.i. but none of the mice at 4 months p.i. Although the C57BL/129 mice developed mild gastritis and typhlocolitis, they had robust immunoglobulin G (IgG) and Th1-promoted IgG2a humoral responses to both the wild-type strain and the C. jejuni cdtB mutant. In contrast, 75 to 100% of the 3X mice were colonized with both the wild type and the C. jejuni cdtB mutant at similar levels at all times examined. Wild-type C. jejuni caused moderately severe gastritis and proximal duodenitis in 3X mice that were more severe than the gastrointestinal lesions caused by the C. jejuni cdtB mutant. Persistent colonization of NF-κB-deficient mice with the wild type and the C. jejuni cdtB mutant was associated with significantly impaired IgG and IgG2a humoral responses (P < 0.001), which is consistent with an innate or adaptive immune system defect(s). These results suggest that the mechanism of clearance of C. jejuni is NF-κB dependent and that CDT may have proinflammatory activity in vivo, as well as a potential role in the ability of C. jejuni to escape immune surveillance. NF-κB-deficient mice should be a useful model to further study the role of CDT and other aspects of C. jejuni pathogenesis.


Sign in / Sign up

Export Citation Format

Share Document